Delcath Systems (DCTH)
(Delayed Data from NSDQ)
$5.71 USD
+0.15 (2.70%)
Updated May 10, 2024 04:00 PM ET
After-Market: $5.73 +0.02 (0.35%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
DCTH 5.71 +0.15(2.70%)
Will DCTH be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for DCTH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for DCTH
Steris (STE) Matches Q4 Earnings Estimates
How Much Upside is Left in Delcath Systems (DCTH)? Wall Street Analysts Think 244.83%
DCTH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Can Delcath Systems (DCTH) Climb 277.73% to Reach the Level Wall Street Analysts Expect?
Delcath Systems (DCTH) Upgraded to Buy: What Does It Mean for the Stock?
Delcath Systems, Inc. (DCTH) Reports Q4 Loss, Tops Revenue Estimates
Other News for DCTH
Delcath Systems to Host First Quarter 2024 Earnings Call
Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
Delcath Systems' Hepzato Kit in melanoma meets primary Phase 3 endpoint
Delcath Systems Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Delcath Systems files to sell 1.92M shares of common stock for holders